Bionoxx Inc.

1 in Phase 3

Quick facts

Phase 3 pipeline

Hydroxyurea (HU) · Oncology; Hematology
Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells.

Phase 1 pipeline

OTS-412

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: